AbbVie Inc. Shares Purchased by Capital Investment Advisors

Institutional investor increases holdings in pharmaceutical company

Mar. 28, 2026 at 7:29am

Got story updates? Submit your updates here. ›

Capital Investment Advisors LLC, an institutional investor, increased its holdings in shares of AbbVie Inc. (NYSE:ABBV) by 2.3% in the fourth quarter, according to a recent SEC filing. The firm now owns 313,064 shares of the pharmaceutical company's stock, valued at $71.5 million.

Why it matters

This investment by Capital Investment Advisors reflects ongoing institutional interest and confidence in AbbVie, a major pharmaceutical company with a diverse product portfolio and pipeline. The increase in holdings suggests the firm sees long-term growth potential in AbbVie's business.

The details

According to the filing, Capital Investment Advisors purchased an additional 7,114 shares of AbbVie in the fourth quarter, bringing its total position to 313,064 shares. AbbVie accounts for about 1.1% of the firm's investment portfolio, making it the 24th largest holding.

  • The increase in holdings occurred in the fourth quarter of the year.

The players

Capital Investment Advisors LLC

An institutional investor that manages a diversified portfolio of investments, including a position in pharmaceutical company AbbVie Inc.

AbbVie Inc.

A global, research-driven biopharmaceutical company that focuses on discovering, developing and commercializing therapies for complex and often chronic medical conditions.

Got photos? Submit your photos here. ›

The takeaway

This investment by Capital Investment Advisors underscores the continued institutional confidence in AbbVie's long-term growth prospects, despite some recent volatility in the stock price. As a major player in the pharmaceutical industry, AbbVie's performance will likely remain a focus for investors and analysts in the coming quarters.